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Figure 1. Ultrasonography showed a mixed echoic large mass 
(6.4×4.8 cm) (arrows) on the right hepatic lobe. There was no 
evidence of cirrhosis in the surrounding liver tissue.
INTRODUCTION
Focal nodular hyperplasia (FNH) is the second most common 
tumor of the liver after hepatic hemangioma.
1 FNH is usually 
asymptomatic, rarely grows or bleeds, and has no malignant 
potential. Therefore, FNH is discovered in most patients 
incidentally during cross-sectional imaging, angiography, 
radionuclide liver scanning, or surgery.
2 Although FNH usually has 
no clinical significance, recognition of its radiologic characteristics 
is important to avoiding unnecessary surgery, biopsy, and 
follow-up imaging. Despite advances in imaging techniques, it is 
still difficult to distinguish between FNH and other focal hepatic 
lesions. Contrast-enhanced ultrasound (CEUS) represents a 
significant breakthrough in sonography and is being increasingly 
used to evaluate focal liver lesions.
3 Herein we present a case of  
FNH of the liver and its characteristic CEUS features.
CASE
A 32-year-old male was admitted with the complaint of an 
asymptomatic liver mass that had been discovered by 
ultrasonography (US) during a medical check-up (Fig. 1). He had 
no previous history of medical illness or alcohol intake. 
Biochemical tests showed that the serum level of alanine 
aminotransferase was 22 IU/L, aspartate aminotransferase was 
19 IU/L, alkaline phosphatase was 75 IU/L, and total bilirubin 
was 0.6 mg/dL. The levels of tumor markers were alpha 
fetoprotein at 5.9 ng/mL, carcinoembryonic antigen at 1.1 ng/mL, 
and carbohydrate antigen 19-9 at 7 U/mL. The results for 
hepatitis B surface antigen, anti-HBs, and anti-hepatitis C virus 
antibody were negative. Computed tomography (CT) and magnetic 
resonance imaging (MRI) revealed a hypervascular mass with a 
central scar in S5 of the liver (Fig. 2). 
CEUS was subsequently performed using a color Doppler 
ultrasonic scanner (Prosound alpha 10 premier, Aloka, Tokyo, 
Japan) with the injection of contrast agent (SonoVue, Bracco 
Diagnosis, Italy) for real-time dual-flame harmonic imaging of 
the mass. The mass appeared spoke-wheel like during the arterial 
phase, and its enhancement persisted until the late phase (Fig. 3, 
Video at www.koreanjhepatol.org ). 















Figure 2. (A-D) CT images obtained at the same level. A high-density mass (arrows) with a low-density center was evident during 
the arterial phase (B). During the portal (C) and delayed (D) phases, the mass was iso-or hypodense. (E) T1-weighted MRI showed 
an isointense lesion with a hypointense central scar (arrows). (F) T2-weighted MRI showed a slightly hyperintense lesion with a more 
hyperintense central scar (arrows). (G) During the arterial phase, in Primovist (gadolinium EOB-DTPA; Schering, Germany)-enhanced 
dynamic T1-weighted MRI the lesion was hyperintense but the central scar remained hypointense. (H) At 20 minutes after Primovist 











Figure 3. (A) Pre-enhanced phase on CEUS. (B-D) During the arterial phase (10~13 seconds after a bolus injecting of contrast agent) 
there was a spoke-wheel-like centrifugal filling of contrast agent and a markedly hyperechoic mass (arrows), which is attributable 
to the presence of a central feeding artery and radial arterial vascularity. Sustained enhancement, which appeared slightly hyperechoic 
or isoechoic relative to the surrounding liver parenchyma, was noticed until the portal venous phase. (E) (45 seconds after contrast-agent 
injection) and the late phase. (F) (3 minutes after contrast-agent injection). The central scar was hypoechoic during all of the phases.416  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Figure 4. Microscopic findings of a biopsy specimen showed 
hyperplasia of normal hepatocytes, a fibrous scar with irregular 
thick-walled blood vessels (arrow), and lymphocytic infiltration 
(H&E stain, ×200).
under ultrasound guidance, and a histologic examination of the 
biopsy specimen showed a fibrous scar with anomalous blood 
vessels (Fig. 4). The characteristic imaging findings and the 
biopsy results led to a final diagnosis of FNH of the liver. He was 
recommended to receive regular follow-up of the hepatic lesion.
DISCUSSION
The prevalence of FNH is approximately 0.9%, and is more 
common in females (80~95% of cases) in the third or fourth 
decade of life.
1 Some studies have shown that FNH develops 
most often in males around the middle age.
4 The pathogenesis of 
FNH is not well characterized. FNH is considered secondary to a 
hyperplastic response to a regenerative nonneoplasic nodule 
caused by a congenital vascular malformation. FNH lesions are 
usually solitary (80% of cases) with diameters >5 cm. Histological 
characteristics include a connective tissue central stellar scar 
with a large arterial vessel and a septum.
5
FNH presents most commonly as an incidental finding on 
hepatic imaging (US, CT, and MRI) with no associated 
symptoms, normal liver function test results, and no elevation of 
serum levels of tumor markers such as alpha fetoprotein. The 
reported incidence of symptomatic lesions in large series has 
ranged from 10% to 59%.
6,7 The most common symptom is 
right-upper quadrant pain. Other symptoms include the 
sensation of a mass in the right-upper quadrant, nausea, and other 
gastrointestinal symptoms. Symptoms do not appear until the 
lesion is large enough to compress surrounding structures or 
induce the sensation of a mass, which on average occurs when 
the size is greater than 7 cm.
7
Given the benign nature of this lesion, it is essential to 
differentiate it from more dangerous liver masses, primarily 
hepatocellular carcinoma. Therefore, the ability to recognize the 
radiologic characteristics of FNH is important to avoiding 
unnecessary surgery, biopsy, and follow-up imaging. FNH is 
typically diagnosed  using several complementary imaging 
techniques. In patients for whom the diagnosis is not clearly 
determined from imaging findings, percutaneous needle biopsy, 
open biopsy, or surgical resection may be needed.
FNH  is diagnosed using imaging modalities based of the 
appearance of a central scar; however, the typical central scar is 
not demonstrated in every patient. The scar may not be visible 
in up to 20% of patients. Moreover, a central scar may be found 
in some patients with fibrolamellar hepatocellular carcinoma, 
hepatic adenoma, or intrahepatic cholangiocarcinoma. This 
limitation applies to all cross-sectional imaging techniques, 
including US, CT, and MRI.
8-10
US examination is a common initial screening method by 
which FNH is discovered. But US findings are variable, 
nonspecific. Dynamic CT after the bolus injection of contrast 
agent adds specificity to the diagnosis, since the lesion becomes 
hyperattenuating relative to the surrounding liver in the arterial 
phase-this typically occurs 20~30 seconds after administering 
the contrast-agent bolus. In the portal venous phase, which 
occurs 70~90 seconds after the bolus injection, FNH is less 
conspicuous and becomes isoattenuating  with the rest of the 
liver. During the delayed phase, at typically 5~10 minutes after 
the bolus injection, FNH is isoattenuating with normal liver 
tissue. While these observations are characteristic of FNH, they 
are not specific, with hypervascular adenomas and carcinomas 
producing similar findings.
11
On MRI, most FNH lesions appear from isointense to 
hypointense on T1-weighted images and from slightly 
hyperintense to isointense on T2-weighted images.
12 The addition 
of intravenous contrast agent greatly improves the specificity of 
MRI. FNH demonstrates a vigorous and nearly homogeneous 
enhancement pattern after the intravenous bolus injection of 
gadolinium. Malignant lesions also present as early enhancement 
after gadolinium injection, but their enhancement is usually not 
homogeneous.
13 
CEUS is a relatively new diagnostic technique that allows the 
assessment of contrast-agent enhancement patterns in real time 
with a substantially higher temporal resolution than other 
imaging modalities (e.g., CT and MRI) and without the need to Ho Suk Kang, et al. Focal nodular hyperplasia  417
predefine scan-time points or to track boluses. Furthermore, 
CEUS can be repeated due to excellent patient tolerance of 
ultrasound contrast agents.
14 FNH is a hypervascular tumor, and 
usually appears in CEUS as a markedly hyperechoic mass 
relative to adjacent normal liver parenchyma in the arterial 
phase. FNH usually shows sustained enhancement in the portal 
venous and late phases, and appears slightly hyperechoic or 
isoechoic relative to the surrounding liver parenchyma.
3 A 
particular of FHN is a spoke-wheel-like fill-in that starts less than 
30 seconds after contrast-agent injection, with one study con-
cluding that this sign is present in 96% of lesions larger than 
3 cm.
15 However, this finding is not pathognomic for FNH when 
the mass  is smaller than 3 cm.
16  Thus, CEUS with another 
contrast agent that allows the evaluation of the enhancement 
patterns of FNH during the late phase,
17 and 3D CEUS, which is 
highly sensitive at assessing tumor vascularization,
18  are 
promising techniques for the evaluation of FNH lesions, 
especially those smaller than 3 cm. 
CEUS is increasingly being performed on a routine basis and, 
in the appropriate clinical setting, included as a part of the 
suggested diagnostic workup of focal liver lesions, and this has 
improved patient management and the cost-effectiveness of 
therapy. This case report has shown the typical imaging patterns 
of FNH in CT, MRI, and CEUS. Especially in CEUS, FNH 
shows spoke-wheel-like contrast-agent filling during the arterial 
phase, which is pathognomic for its diagnosis.
SUMMARY
Despite advances in imaging techniques and the ability to 
detect hepatic masses, it is still difficult to distinguish between 
FNH and other liver lesions. CEUS may be a useful diagnostic 
method for FNH lesions larger than 3 cm that show a typical 
spoke-wheel pattern.
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